Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy.
Neonatal thrombocytopenia affects 20-40% of the infants in intensive care units. The frequency of neonatal alloimmune thrombocytopenia (NAIT) is estimated at 1/1500 to 1/5000 live births. The risk of morbidity is significant with 20% neurological sequelae and the death rate is estimated at 10% of affected infants. During recent years considerable efforts have been made to prevent fetal bleeding and to avoid birth trauma, which have significantly changed the natural history of NAIT.
Kaplan
C
C
Service d'Immunologie Leuco-Plaquettaire, INTS, Paris, France.
Morel-Kopp
M C
MC
Clemenceau
S
S
Daffos
F
F
Forestier
F
F
Tchernia
G
G
D016824:Antigens, Human Platelet / Q000276:immunology; D016913:Blood Component Transfusion; D001792:Blood Platelets / Q000276:immunology; D001805:Blood Transfusion, Intrauterine; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D005315:Fetal Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy; D006470:Hemorrhage / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007112:Immunity, Maternally-Acquired; D015994:Incidence; D007231:Infant, Newborn; D007518:Isoantibodies / Q000276:immunology*; D010976:Platelet Count; D017713:Platelet Transfusion; D011247:Pregnancy; D011256:Pregnancy Outcome; D011296:Prenatal Diagnosis; D012307:Risk Factors; D013921:Thrombocytopenia / Q000151:congenital* / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D016896:Treatment Outcome
D016824:Antigens, Human Platelet; D007518:Isoantibodies